NCT04164199 2026-03-16
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
BeOne Medicines
Phase 3 Enrolling by invitation
Clinical Trials
20 trialsNCT06435312 2026-03-13
ziMyG+
UCB Pharma
Phase 3 Enrolling by invitation
NCT06540144 2026-02-27
An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Enrolling by invitation
NCT05303532 2026-02-23
ROSY-D
AstraZeneca
Phase 3 Enrolling by invitation
NCT07348575 2026-01-16
A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma
Second Affiliated Hospital of Nanchang University
Phase 3 Enrolling by invitation
NCT05645536 2026-01-12
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Tolmar Inc.
Phase 3 Enrolling by invitation
NCT07311057 2026-01-06
Investigation of Effect of Formulated Methylene Blue on Treatment of Squamous Cell Carcinoma Skin Cancer in Inoperable Patients and Not Suitable for Radiotherapy
Mashhad University of Medical Sciences
Phase 3 Enrolling by invitation
NCT07311070 2026-01-06
Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue
Mashhad University of Medical Sciences
Phase 3 Enrolling by invitation
NCT06281964 2025-12-16
KANNON-2
Avistone Biotechnology Co., Ltd.
Phase 3 Enrolling by invitation
NCT07258680 2025-12-02
BrEto-TCL
N.N. Petrov National Medical Research Center of Oncology
Phase 3 Enrolling by invitation
NCT07149506 2025-09-08
OCTOPUS-RD
Universidad de Guanajuato
Phase 3 Enrolling by invitation
NCT06950190 2025-08-12
(ECCPC)
Ellis Medicine
Phase 3 Enrolling by invitation
NCT07084454 2025-07-24
GAIN-S
Instituto Oncoclinicas
Phase 3 Enrolling by invitation
NCT07016737 2025-06-12
ESO-Nanjing12
Jiangsu Cancer Institute & Hospital
Phase 3 Enrolling by invitation
NCT03507842 2025-03-17
A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML.
Asan Medical Center
Phase 3 Enrolling by invitation
NCT06857305 2025-03-04
Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Enrolling by invitation
NCT05674539 2025-02-10
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3 Enrolling by invitation
NCT06759857 2025-01-06
FHND9041
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Phase 3 Enrolling by invitation
NCT06671418 2024-11-04
TESLA RCT
Erasmus Medical Center
Phase 3 Enrolling by invitation
NCT04762459 2022-02-24
APEX
ChineseAMS
Phase 3 Enrolling by invitation